Content about Ranbaxy Laboratories

November 1, 2011
Pfizer could lose No. 1 global sales ranking to Sanofi next year, report finds

Pfizer soon may lose its distinction of having the highest global sales of any drug company, according to life sciences industry analysis firm EvaluatePharma.

September 8, 2011
Report: Ranbaxy to launch generic Lipitor at end of November

Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

September 1, 2011
Dr. Reddy's, Pfizer settle over Lipitor

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

August 19, 2011
Report: Ranbaxy may sell generic Lipitor rights if unable to get FDA approval

While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can't win Food and Drug Administration approval in time, according to published reports.

July 19, 2011
Ranbaxy to produce, market antiretrovirals under licensing agreement with Gilead

Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.

June 7, 2011
Mylan subsidiary gets OK for generic Aricept

Another generic drug maker has been given the green light to market its version of an Alzheimer's disease treatment.

May 3, 2011
Mylan's Q1 sales increase by 12%; judge dismisses case against FDA

Sales at generic drug maker Mylan increased by 12% during first quarter 2011, compared with first quarter 2010, the company said Tuesday.

March 21, 2011
Report: Mylan looks to block Ranbaxy from making generic Lipitor

Generic drug maker Mylan is suing the Food and Drug Administration in an effort to prevent Gurgaon, India-based competitor Ranbaxy Labs from launching its generic version of Pfizer’s cholesterol medication Lipitor, according to published reports.

February 1, 2011
Generics to save $70 bn

NEW YORK — The U.S. healthcare system could get at least $70 billion in savings over the next four years thanks to loss of patent protection for branded drugs, according to published reports.


IMS Health SVP Murray Aitken said at the Reuters Health Summit that generics also would increase their dominance in terms of prescriptions dispensed, increasing from 77% during the first half of this year to perhaps 85% by 2014, Reuters reported.


January 5, 2011
Pfizer seeks to stop generic versions of Lipitor

A generic version of the world’s top-selling cholesterol treatment is expected to hit the market this year, but the branded version’s manufacturer is trying to put the brakes on the launch, according to media reports.

December 22, 2010
Takeda settles patent suits relating to Actos

Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.

November 30, 2010
Ranbaxy launches generic Aricept

Ranbaxy Pharmaceuticals has received final approval for its generic Alzheimer's drug from the Food and Drug Administration, giving the drug maker 180 days of market exclusivity.

November 14, 2010
Countdown to 2011: A big year for generics

The world of generic drugs has a big year ahead of it. Actually, it has...

November 8, 2010
IMS Health executive: Generic competition can help U.S. save billions

Loss of patent protection for branded drugs and subsequent competition from generics could save the...

October 4, 2010
Report: Ranbaxy to market generic Aricept

Ranbaxy has won the right to sell a generic version of an Alzheimer’s disease drug...

August 11, 2010
Ranbaxy head steps down

The CEO of Ranbaxy Labs will step down next week, the Indian generic drug maker...

June 6, 2010
Specialty Rx offers pharma a patent cliff parachute

While Big Pharma hurdles toward the edge of the patent cliff, some of the latest...

May 19, 2010
Watson subsidiary launches generic Lipitor

A subsidiary of generic drug maker Watson Pharmaceuticals has launched a version of a cholesterol-lowering...

May 11, 2010
Ranbaxy sales exceed $500 million for the first time

Ranbaxy Labs had net sales of $542 million and profits of $210 million in first...

March 29, 2010
FTC wins pay-for-delay battle

The Federal Trade Commission’s crusade against patent settlements between branded and generic drug makers moved...

March 14, 2010
Ranbaxy to launch generic Actos

India’s Ranbaxy Labs will launch a generic version of a diabetes drug in two years,...

January 18, 2010
Ranbaxy gears up to develop vaccines

Ranbaxy Labs has made a foray into the world of vaccines, the generic drug maker...

© 2013 Drug Store News. All Rights Reserved.